The sixth international RASopathies symposium: Precision medicine-From promise to practice

Area of Science:

• Genetics
• Molecular Biology
• Medical Science

Background:

• RASopathies are a group of genetic disorders stemming from germline pathogenic variants in RAS-mitogen activated protein kinase (MAPK) pathway genes.
• These disorders are characterized by RAS/MAPK pathway dysregulation, leading to shared phenotypic manifestations across multiple organ systems.
• The lifelong and potentially life-limiting medical complications associated with RASopathies highlight the need for advanced treatment strategies.

Framework:

• The Sixth International RASopathies Symposium convened experts to focus on precision medicine approaches for RASopathies.
• Attendees included basic scientists, clinicians, patient advocates, and pharmaceutical and governmental representatives.
• Discussions centered on novel RASopathy genes, variants, and animal models relevant to therapeutic development.

Implementation:

• The symposium explored current medication trials and drug development pipelines for RASopathies.
• Key discussions involved establishing and measuring meaningful endpoints for clinical treatment trials.
• Strategies for ensuring drug availability to patients post-trial completion were also addressed.

Implications:

• Advancements in understanding RASopathies and their genetic underpinnings are paving the way for targeted therapies.
• Precision medicine holds significant promise for improving outcomes and managing complications in patients with RASopathies.
• Collaborative efforts among researchers, clinicians, and industry stakeholders are crucial for accelerating drug development and patient access.